Ivantis Inc. reported primary and secondary endpoints have been met for a pivotal study of its Hydrus microstent micro-invasive glaucoma surgical (MIGS) device. Outcomes from the Horizon study have outstripped previous MIGS trials, according to the company, which anticipates FDA approval in 2018.